Samuel Scofield
Senior Associate at Good Growth Capital
New York, New York
Overview
Work Experience
Senior Associate
2023 - Current
Associate
2022 - 2023
Investing in early-stage life sciences companies Therapeutics: AdipoPharma, Tevard Biosciences Medical devices: Avisi Technologies, Coaptech, Pleural Dynamics, Relief Cardiovascular, Spiro Robotics, Venostent Diagnostics: AOA Dx Biomanufacturing: Aralez Bio Ag-Biotech: Robigo
Good Growth Capital invests in early-stage transformative science- and technology-based companies
Board Observer
2025
Avisi Technologies develops a nanotechnology-enabled defense against blindness from glaucoma.
Raised $10,225,500.00 from Life Sciences Greenhouse of Pennsylvania, Life Science Angels, Kyto Technology and Life Science Inc, Ben Franklin Technology Partners of Southeastern Pennsylvania, Gaingels, Good Growth Capital, Mountain State Capital, Sunstone Management, Accanto Partners and MedVenture Partners.
Board Observer
2024
Board Observer
2023
Board Observer
2023
AOA Dx is a biotech company developing cancer diagnostics in the field of women’s health.
Raised $24,500,000.00 from Gore Range Capital, LabCorp Venture Fund, Good Growth Capital, Astia, The Helm, RH Capital, LongeVC, VU Venture Partners, Cancer Fund and Adaptive Capital Partners.
Board Observer
2023
Board Observer
2023
VenoStent is a tissue engineering medical device company developing bioabsorbable polymer wraps for better outcomes in vascular surgery.
Raised $29,818,706.00 from Good Growth Capital, Norwest Venture Partners, IAG Capital Partners, Creative Ventures, SNR.vc, TMC Venture Fund, IAG Capital Partners, Alumni Ventures and Baylor Angel Network.
Associate
2022 - 2022
Senior Analyst
2020 - 2022